Trial Profile
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloid polyneuropathy; Familial amyloid neuropathy
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms NEURO-TTR OLE
- Sponsors Ionis Pharmaceuticals
- 14 Nov 2022 Results assessing longer-term efficacy and safety data for inotersen, with a median treatment exposure of 3 years,published in the Journal of Neurology.
- 01 Oct 2022 Results of an analysis assessing the long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy published in the Muscle and Nerve
- 22 Jun 2021 Results assessing efficacy and safety with greater than 3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis, presented at the 7th Congress of the European Academy of Neurology